TENAX THERAPEUTICS, INC. cotiza a 1.60 USD y tiene una capitalización bursátil de $60M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with prese…
| Periodo | 2026-07 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.35 | $-0.35 | $-0.38 | $-0.40 |
| Estimado | $-0.36 | $-0.40 | $-0.41 | $-1.12 |
| Sorpresa | +2.8% | +12.5% | +7.3% | +64.3% |
| Métrica | TENX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -54.2% | -40.4% | -13.8% |
| ROA | -50.5% | -32.0% | -18.5% |
| Current Ratio | 14.56 | 2.84 | +11.72 |
| Debt / Equity | — | 0.28 | — |